Cardiff Oncology Statistics
Share Statistics
Cardiff Oncology has 66.52M
shares outstanding. The number of shares has increased by 48.74%
in one year.
| Shares Outstanding | 66.52M |
| Shares Change (YoY) | 48.74% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 59.89% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 61 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 17.34M, so 26.06% of the outstanding
shares have been sold short.
| Short Interest | 17.34M |
| Short % of Shares Out | 26.06% |
| Short % of Float | 26.57% |
| Short Ratio (days to cover) | 9.68 |
Valuation Ratios
The PE ratio is -4.55 and the forward
PE ratio is -2.85.
Cardiff Oncology's PEG ratio is
-2.12.
| PE Ratio | -4.55 |
| Forward PE | -2.85 |
| PS Ratio | 302.78 |
| Forward PS | 1.6 |
| PB Ratio | 2.49 |
| P/FCF Ratio | -5.47 |
| PEG Ratio | -2.12 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cardiff Oncology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.08,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.08 |
| Quick Ratio | 7.08 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $21,343.75 |
| Profits Per Employee | $-1,419,718.75 |
| Employee Count | 32 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -24K |
| Effective Tax Rate | 0.05% |
Stock Price Statistics
The stock price has increased by -20.17% in the
last 52 weeks. The beta is 1.73, so Cardiff Oncology's
price volatility has been higher than the market average.
| Beta | 1.73 |
| 52-Week Price Change | -20.17% |
| 50-Day Moving Average | 3.4 |
| 200-Day Moving Average | 3.14 |
| Relative Strength Index (RSI) | 44.1 |
| Average Volume (20 Days) | 1,215,033 |
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 683K
and earned -45.43M
in profits. Earnings per share was -0.95.
| Revenue | 683K |
| Gross Profit | 279K |
| Operating Income | -48.65M |
| Net Income | -45.43M |
| EBITDA | -48.65M |
| EBIT | -48.65M |
| Earnings Per Share (EPS) | -0.95 |
Full Income StatementBalance Sheet
The company has 51.47M in cash and 1.52M in
debt, giving a net cash position of 49.95M.
| Cash & Cash Equivalents | 51.47M |
| Total Debt | 1.52M |
| Net Cash | 49.95M |
| Retained Earnings | -384.18M |
| Total Assets | 97.19M |
| Working Capital | 81.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -37.69M
and capital expenditures -80K, giving a free cash flow of -37.77M.
| Operating Cash Flow | -37.69M |
| Capital Expenditures | -80K |
| Free Cash Flow | -37.77M |
| FCF Per Share | -0.79 |
Full Cash Flow StatementMargins
Gross margin is 40.85%, with operating and profit margins of -7123.13% and -6651.68%.
| Gross Margin | 40.85% |
| Operating Margin | -7123.13% |
| Pretax Margin | -6655.2% |
| Profit Margin | -6651.68% |
| EBITDA Margin | -7123.13% |
| EBIT Margin | -7123.13% |
| FCF Margin | -5530.45% |
